Introduction:

My Dose Coach™ (MDC) is a U.S. Food and Drug Administration-approved digital smartphone application designed to help users with type 2 diabetes mellitus (T2DM) to titrate their basal insulin (BI) according to a clinician-prescribed individualized titration plan. The present analysis aimed to compare the efficacy of the MDC app in achieving the fasting plasma glucose (FPG) target, glycemic goals (glycated hemoglobin [HbA1c] <7%), hypoglycemic events, and economic costs with conventional titration strategies in people with T2DM in Mexico.

Methods:

This randomized, controlled, single-center, two-arm, 12-week clinical trial included insulin-naïve participants with uncontrolled T2DM (HbA1c 8%–10%). The study endpoints included the number of participants achieving a weekly mean FPG of 90–130 mg/dL, time to reach the FPG target, reduction in HbA1c, the mean number of insulin applications and FPG measurements per month, hypoglycemia incidence, and cost-effectiveness.

Results:

Study participants (N = 80) were divided equally into control and MDC arms. The percentage of participants achieving the target FPG range was higher (92.5% vs. 75.0%; P = 0.034) in the MDC arm with a greater reduction in fasting glucose (69.0 vs. 62.0 mg/dL; P = 0.028) compared with the control arm. The MDC group achieved the fasting glucose target faster than the control group (18 vs. 30 days; P = 0.001). After 12 weeks, both groups had a reduction in HbA1c levels. The MDC group had a fewer hypoglycemia events than the control group. No severe or nocturnal hypoglycemia was reported in either study arm. The cost of care was lower in the MDC group than in the control group (Mex$4890.00 vs. Mex$7582.00; P = 0.001).

Conclusions:

The MDC app is a viable option which can be used for titrating BI dose in a safe, effective, and cost-efficient manner for individuals with T2DM in Mexico.

Search results

Efficacy,Safety,and Economic Impact of a Basal Insulin Titration App,My Dose Coach™,in People with Type 2 Diabetes Mellitus in Mexico